Teva says it will cut costs and innovate more
December 12 2012
The drugmaker told investors Tuesday that generics will remain its standby, but novel therapeutic entities are also in its future.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.